Morgan Stanley analyst David Lebowitz maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and lowers the price target from $201 to $197.
Morgan Stanley Maintains Overweight on Ascendis Pharma, Lowers Price Target to $197
Morgan Stanley analyst David Lebowitz maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and lowers the price target from $201 to $197.
Related Posts
Decibel Preliminary Q2 2022 Outlook Shows Net Revenue And Adjusted EBITDA Growth
Decibel Cannabis Company Inc. (OTCQB: DBCCF) (TSX-V:DB) provided a preliminary outlook for net revenue and Adjusted EBITDA for the second quarter, ending June 31, 2022.
Q2 2022 Outlook
ScottsMiracle-Gro Reduces Outlook For Sales And Non-GAAP Adjusted EPS, Here Are The Details
The Scotts Miracle-Gro Company (NYSE: SMG) stated consumer purchases of its core lawn and garden brands surged in May with unit volume now trending towards the company’s original assumptions for the season.
Paycor HCM Q4 EPS $(0.23) May Not Compare To $0.03 Estimate, Sales $88.00M Beat $85.66 Estimate
Paycor HCM (NASDAQ:PYCR) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $0.03 by 866.67 percent. The company reported quarterly sales of $88.00 million which beat the